Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, July 19, 2017

Long-term Use of Ampyra Lowers Medical Costs, Hospital Visits for MS Patients, Study Finds

Click here to receive MS news via e-mail

Written by Ed Tobias

I used Ampyra for a few years and I thought it helped my walking, increasing my speed and stability a bit. So, I’m not surprised that this study reports benefits that I’d expect would follow an improvement of MS systems. But, be aware that this study was paid for by Acorda Therapeutics, the manufacturer of Ampyra.
A recent study has found that continued use of Ampyra (dalfampridine extended-release, sold in the U.S. by Acorda Therapeutics) by patients with multiple sclerosis (MS) lowers both inpatient hospital visits and overall healthcare costs.
Specifically, the authors reported that persistent use of Ampyra was associated with a 3.3% probability of hospital admission compared to 6.4% in patients with non-persistent use.

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: 

No comments: